Skip to main content
. 2015 Jul 4;15:495. doi: 10.1186/s12885-015-1512-6

Fig. 2.

Fig. 2

Overall survival. Overall survival Kaplan-Meier curves in all patients receiving only everolimus + lanreotide (n = 57) or sunitinib + lanreotide (n = 50), in patients with pNETs receiving everolimus + lanreotide (n = 27) or sunitinib + lanreotide (n = 28), and in patients with extrapancreatic neuroendocrine tumours receiving everolimus + lanreotide (n = 30) or sunitinib + lanreotide (n = 22)